肿瘤细胞治疗研究
英文原题：Decoding the immune microenvironment: precision immunotherapy for medulloblastoma subtypes.
髓母细胞瘤是一种严重的儿童脑肿瘤，具有不同的分子亚型——WNT、SHH、第3组和第4组——每种亚型都有独特的遗传驱动因素和免疫微环境。
髓母细胞瘤是一种严重的儿童脑肿瘤，具有不同的分子亚型——WNT、SHH、Group 3和Group 4——每种亚型都有独特的遗传驱动因素和免疫微环境。本综述重点介绍了每种亚型的免疫特征：SHH富含肿瘤相关巨噬细胞（TAMs），其在肿瘤发生中的作用存在争议；Group 3以细胞毒性T细胞为特征，这些细胞常被PD-L1等免疫检查点中和，导致T细胞耗竭；Group 4以自然杀伤（NK）细胞和B细胞为标志。这些免疫景观，包括肿瘤相关星形胶质细胞（TAAs）和异常血管网络，影响肿瘤生长、扩散和治疗反应。精准免疫治疗必须针对特定亚型量身定制。本文讨论了针对SHH亚型中常见的B7-H3和GD2等抗原的CAR T细胞疗法，并探讨了靶向PD-1/PD-L1和CD47-SIRP的免疫检查点阻断。文章还强调了创新方法，如利用溶瘤病毒将“冷”肿瘤微环境转化，以及使用CSF1R抑制剂和肿瘤相关抗原的组合疗法来增强抗肿瘤反应。理解髓母细胞瘤免疫微环境的亚型特异性异质性对于推进精准免疫治疗和改善患者预后至关重要。
Medulloblastoma is a severe pediatric brain tumor with distinct molecular subtypes-WNT, SHH, Group 3, and Group 4-each having unique genetic drivers and immune microenvironments. This review highlights the immune characteristics of each subtype: SHH is rich in tumor-associated macrophages (TAMs), whose role in tumorigenesis is debated; Group 3 features cytotoxic T cells often neutralized by immune checkpoints like PD-L1, causing T cell exhaustion; and Group 4 is marked by natural killer (NK) cells and B cells. These immune landscapes, including tumor-associated astrocytes (TAAs) and abnormal vascular networks, influence tumor growth, spread, and treatment response. Precision immunotherapy must be tailored to specific subtypes. This article discusses CAR T-cell therapy targeting antigens like B7-H3 and GD2, prevalent in SHH subtypes, and examines immune checkpoint blockades targeting PD-1/PD-L1 and CD47-SIRP . It also highlights innovative methods like oncolytic viruses to transform "cold" tumor microenvironments and combination therapies using CSF1R inhibitors and tumor-associated antigens to boost anti-tumor responses. Understanding the immune microenvironment's subtype-specific heterogeneity in medulloblastoma is crucial for advancing precision immunotherapy and improving patient outcomes.
MEMBER ACCOUNT
登录成功会直接打开下一页。
